Delivered as a once-daily 30 mg/mL IV bolus injection over 15 seconds, Xifyrm can be used alone or alongside non-NSAID ...

Nicolette Natale, D.O., whose areas of expertise include the treatment of substance abuse disorders. Courtesy Nicolette Natale, D.O. According to ...

Journavx received FDA approval, the agency announced on Thursday, Jan. 30. The drug developed by Boston-based Vertex Pharmaceuticals blocks sodium channels in the peripheral nervous system ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Vertex's Journavx, targeting NaV1.8, is FDA-approved and shows opioid-level pain relief with fewer side effects, positioning it as a potential new standard of care. Eli Lilly's acquisition of ...

UT Health San Antonio Multispecialty and Research Hospital says it’s the first in Texas to add a new non-opioid medication to ...

DAVENPORT, Iowa (KWQC) - The Food and Drug Administration recently approved Journavx to treat short-term pain. It’s a new class of non-opioid pain medication for treating adults and the first ...

Look for Journavx to become a massive blockbuster drug for Vertex. It won U.S. Food and Drug Administration (FDA) approval earlier this year for treating acute pain. The big plus for Journavx is that ...

In January, Vertex achieved a significant milestone with the FDA approval of Suzetrigine, marketed under the brand name Journavx. The approval was the first new class of nonopioid pain medication ...

Vertex’s Journavx is the product of the pharma company’s internal NaV1.8 research. This twice-daily pill was awarded FDA approval in January as a treatment for moderate-to-severe acute pain in ...